Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

------------------------- Combined Protocols 7858 4 7861 83 95.2 (87.2, 98.7) ====================================================================== HPV 6-, 11-, 16-, or 18-related Genital Warts ---------------------------------------------------------------------- Protocol 007 235 0 233 3 100.0 (-139.5, 100.0) ---------------------------------------------------------------------- FUTURE I 2261 0 2279 29 100.0 (86.4, 100.0) ---------------------------------------------------------------------- FUTURE II 5401 1 5387 59 98.3 (90.2, 100.0) ---------------------------------------------------------------------- Combined Protocols 7897 1 7899 91 98.9 (93.7, 100.0) ---------------------------------------------------------------------- * The PPE population consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naive (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). **See Table 2 for analysis of vaccine impact in the general population. ***Evaluated only the HPV 16 L1 VLP vaccine component of GARDASIL. +P-values were computed for pre-specified primary hypothesis tests. All p-values were less than0.001, supporting the following conclusions: efficacy against HPV 16/18-related CIN 2/3 is greater than0% (FUTURE II); efficacy against HPV 16/18-related CIN 2/3 is greater than25% (Combined Protocols); and efficacy against HPV 6/11/16/18-related CIN is greater than20% (FUTURE I). ++Analyses of the combined trials were prospectively planned and included the use of similar study entry criteria. n = Number of subjects with at least 1 follow-up visit after Month 7. Note 1: Point estimates and confidence intervals are adjusted for person-time of follow-up.
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:7/25/2014)... NEW YORK , July 25, 2014  Smile ... selected to showcase their Virtual Surgery Simulator among ... 2014, which will take place in Washington, ... for the Performing Arts. "Smile Train ... BioDigital alongside the talented community of innovators in health ...
(Date:7/25/2014)... GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased to announce the ... LLC, an Illinois limited liability company ... medical marijuana licenses in the state of Illinois ... 20% equity interest in LaurelCo, LLC in exchange for licenses ... well as all technology related to the machines and to ...
(Date:7/25/2014)...  Solanbridge Group Inc (OTC: SLNX) is pleased to ... Buzznbrewz.com and the Letter of Intent issued on July ... Purchase Agreement. Charles R. Shirley , ... have Mr. David Pecoraro and Buzznbrewz.com join ... private sector and developed a tremendous network of contacts ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... Genoptix, Inc. (Nasdaq: GXDX ), a specialized ... for the third quarter of 2009, which includes a ... primarily from strong cash collections related to prior period ... of $32.1 million for the comparable period in 2008, ...
... (Nasdaq: ROCM ) today announced operating results for its ... Company reported sales of $9,009,000 for the current quarter compared ... The Company reported a quarterly net loss of $229,000 or ... or $.03 per diluted share for the fourth quarter of ...
Cached Medicine Technology:Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 3Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 4Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 7Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 8Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 9Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 10Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert 12
(Date:7/26/2014)... July 26, 2014 The European security ... at $1290 million in 2014, and it is expected ... of 6.16%. The report incorporates the factors that influence ... of growth rates and projected total expenditure. The report ... global markets. Apart from the general overview of the ...
(Date:7/26/2014)... gas chromatography reagents report defines and segments the concerned market ... chromatography reagents market in Europe is valued at $ 314.8 ... $445.5 million by 2018, at a CAGR of 8.6 %, ... the European gas chromatography reagents market, to get an idea ... glimpse of the segmentation of gas chromatography reagents market in ...
(Date:7/26/2014)... July 26, 2014 (HealthDay News) -- Pools can provide ... make themselves sick if they swallow too much chlorinated ... it,s common for little ones to get water in ... from a pool, despite warnings from their parents. ... harmless, it,s important for parents to realize that ingesting ...
(Date:7/26/2014)... Dallas,Texas (PRWEB) July 26, 2014 “BRIC ... on the BRIC Sinuscopes market. The report provides value, ... average prices (in US dollars) within market segments – ... shares and distribution shares data for each of these ... market participants, pipeline products, and news and deals related ...
(Date:7/26/2014)... Everett, WA (PRWEB) July 26, 2014 “Healthy ... important in keeping those pearly whites shining,” says Community Health ... Your Teeth Healthy ." , They believe that an integration ... keep people healthy and well. Because of this, they encourage ... but also with dentist . , “Children and adults ...
Breaking Medicine News(10 mins):Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 4Health News:Europe Security and Surveillance Radar Market is Expected to Reach $1800 million in 2019 - New Report by MicroMarket Monitor 5Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:Don't Let Kids Drink Pool Water 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2
... Pa., Nov. 24 WPCS International,Incorporated (Nasdaq: ... services for,specialty communication systems and wireless infrastructure, has ... $9 million in,new contracts. The contracts include projects ... Office of Emergency Management, YMCA, Group,Health Tacoma, UPS, ...
... ARAY ), a global leader in the field of radiosurgery, ... 20th Annual Piper Jaffray,Health Care Conference in New York City, ... PST). , A live ... relations page of the Company,s Web site at http://www.accuray.com ...
... 24 According to a new survey released,today, the vast majority ... percent -- are not taking the most basic steps of determining ... test if they are at,risk or taking the appropriate actions as ... baseline among Americans on their level of awareness and,knowledge regarding type ...
... Fight Against AIDS with their "Love for Life" Limited Edition ... 24 ALDO, a global fashion footwear and accessories ... program of the global health organization Population Services International, continues ... bracelets. ALDO has given more than $10 million ...
... of Drugs with Broad Potential to Treat Life-Threatening Viral Infections-- ... Agent Bavituximab and Equivalent Antibodies Cured Lethal Viral Infections in ... Confirms PS is a ,Druggable, Target Common to a Number ... TUSTIN, Calif., Nov. 24 Peregrine Pharmaceuticals, Inc. (Nasdaq: ...
... Cepheid,(Nasdaq: CPHD ) today announced that ... its Xpert(TM) MRSA/SA Skin and Soft Tissue (SSTI) ... (MRSA) and,Staphylococcus aureus (SA, typically Methicillin-sensitive) in skin ... MRSA/SA SSTI test is expected to,empower Canadian physicians ...
Cached Medicine News:Health News:WPCS Announces $9 Million in New Contracts 2Health News:Accuray Incorporated to Present at 20th Annual Piper Jaffray Health Care Conference 2Health News:New Survey Shows Majority of Americans Need to Take Proper Steps to Manage Diabetes Risk 2Health News:New Survey Shows Majority of Americans Need to Take Proper Steps to Manage Diabetes Risk 3Health News:New Survey Shows Majority of Americans Need to Take Proper Steps to Manage Diabetes Risk 4Health News:ALDO Supports World AIDS Day by Donating 100% of Proceeds for Newest 'ALDO Fights Aids' Product 2Health News:ALDO Supports World AIDS Day by Donating 100% of Proceeds for Newest 'ALDO Fights Aids' Product 3Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 2Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 3Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 4Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 5Health News:Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections 6Health News:Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections 2Health News:Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections 3Health News:Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections 4
Stainless steel bone clamp....
Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
Straight double action bone cutting rongeur....
Medicine Products: